What To Know: Tonix announced on Tuesday that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL, removing a potential roadblock in the approval process. This decision brings the company one step closer to a potential Q4 2025 launch, pending final FDA approval.

Read Also: What’s Going On With Cava Group Stock Thursday?

CEO Seth Lederman emphasized the drug’s potential to introduce a new class of fibromyalgia treatments, offering hope to millions of patients struggling with this chronic pain disorder.

TNX-102 SL is a sublingual formulation of cyclobenzaprine HCl, designed to improve symptom management in fibromyalgia patients. The drug was granted Fast Track designation in 2024, expediting its regulatory review.

Tonix says the company remains optimistic about the drug's potential to provide a new, effective treatment option for patients seeking relief.

Read Also: GM, Ford, Tesla And Other Auto Stocks Slide In Thursday Pre-Market: What’s Going On?

How To Buy TNXP Stock

By now you're likely curious about how to participate in the market for Tonix Pharmaceuticals – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

In the case of Tonix Pharmaceuticals, which is trading at $25.76 as of publishing time, $100 would buy you 3.88 shares of stock.

According to data from Benzinga Pro, TNXP has a 52-week high of $1,146.01 and a 52-week low of $6.76.